Imipenem/cilastatin is the first of a new class of β-lactam antibiotics called carbapenems. The antibacterial spectrum of imipenem exceeds any antibiotic investigated to date and includes gram-positive, gram-negative, and anaerobic organisms. Only methicillin-resistant organisms, Strep. faecium, Pseudomonas cepacia, and Pseudomonas maltophilia have been shown to be resistant. Imipenem is administered in a 1:1 ratio with cilastatin, which inhibits a renal enzyme (dehydropeptidase) and improves urinary recovery of imipenem. The elimination half-life of both compounds is 1.0 hours and recommended doses are 0.25–0.5 g iv q6h. Adverse events are similar in nature and incidence to β-lactam antibiotics, with phlebitis/thrombophlebitis, diarrhea, nausea, skin rash, and elevations of hepatic enzymes most common.
Clinical studies in phase II and III trials have shown imipenem/cilastatin to be effective in soft tissue infections, endocarditis, obstetrics and gynecology, complicated urinary tract infections, mixed anaerobic-aerobic infections, osteomyelitis, bacteremias, and pneumonias. Several comparative clinical trials have shown imipenem/cilastatin to be equal in efficacy to combination therapy. Imipenem/cilastatin may prove to be an alternative to combination antibiotic therapy because of its extremely broad spectrum of activity.
KAHANJS, KAHANFM, GOEGELMANSA, etal. Thienamycin, a new β-lactam antibiotic. I. Discovery, taxonomy, isolation, and physical properties. J Antibiot (Tokyo)1979; 32: 1–12.
2.
BIRNBAUMJ, KAHANFM, KROPPH, MACDONALDJS. Carbapenems, a new class of beta-lactam antibiotics: discovery and development of imipenem/cilastatin. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 3–21.
3.
NEUHC. Structure-activity relations of new beta-lactam compounds and in vitro activity against common bacteria. Rev Infect Dis1983; 5: S319–37.
4.
SPRATTBG, TOBANPUTRAV, ZIMMERMANW.Binding of thienamycin and clavulanic acid to the penicillin-binding proteins of E. coli K-12. Antimicrob Agents Chemother1977; 12: 406–9.
5.
HASHIZUMET, ISHINOF, NAKAOAWAJ, TAMAKIS, MATSUHASHIM.Studies on the mechanism of action of imipenem (N-formimidoyl thienamycin) in vitro: binding to the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBP's in E. coli. J Antibiot (Tokyo)1984; 37: 394–9.
6.
KROPFH, SUNDELOFJG, HAJDUR, etal. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-1. Antimicrob Agents Chemother1982; 22: 62–70.
7.
NORRBYSR, ALESTIGK, BJORNEGARDB, etal. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother1983; 23: 300–7.
8.
JONESRN. Review of the in vitro spectrum of activity of imipenem. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 22–32.
9.
KAHANFM. KROPP H, SUNDELOF JG. BIRNBAUM J. Thienamycin: development of imipenem-cilastatin. J Antimicrob Chemother1983; 12: 1–35.
10.
TALLYFP, JACOBUSNV. Susceptibility of anaerobic bacteria to imipenem. J Antimicrob Chemother1983; 12: 47–51.
11.
CORRADOML, LANDESMANSH, CHERUBINCE. Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) againstPseudomonas aeruginosa. Antimicrob Agents Chemother1980; 18: 893–6.
12.
BUSTAMANTECI, DRUSANOGL, TATEMBA, STANDIFORDHC. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother1984; 26: 678–82.
13.
WEXLERHM, FINEGOLDSM. Impact of imipenem/cilastatin on normal fecal flora. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 41–6.
14.
CALANDRAGB, BROWNKR, GRADLC, AHONKHAIVI, WANGC, AZIZMA. Review of adverse experiences and tolerability in the first 2516 patients treated with imipenem/cilastatin. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 73–8.
15.
NORRBYR, ROGERSJD, JONESKH, KAHANFM, MEISINGERMA, ROGERSJD. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. Antimicrob Agents Chemother1983; 23: 293–9.
16.
NORRBYSR, BJORNEGARDB, FERBERF, JONESKH. Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother1983; 12: 109–24.
17.
NORRBYSR, ROGERSJD, JONESKH, etal. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Chemother1984; 26: 707–14.
VERPOOTENGA, VERBISTL, BUTINXAP, ENTWISTLELA, JONESKH, DE BROEME. The pharmacokinetics of imipenem (thienamycinformamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. Br J Clin Pharmacol1984; 18: 183–93.
20.
GIBSONTP, DEMETRIADESJL, BLANDJA. Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 54–61.
21.
FREIJBJ, MCCRACKENGH, OLSENKD, THRELKELDN.Pharmacokinetics of imipenem-cilastatin in neonates. Antimicrob Agents Chemother1985; 27: 431–5.
22.
GRUBERWC, RENCHMA, GARCIA-PRATSJA, EDWARDSMS, BAKERCJ. Single-dose pharmacokinetics of imipenem-cilastatin in neonates. Antimicrob Agents Chemother1985; 27: 511–4.
23.
JACOBSRF, KEARNSGL, TRANGJM, etal. Single-dose pharmacokinetics of imipenem in children. J Pediatr1984; 105: 996–1001.
24.
REEDMD, STERNRC, O'BRIENCA, YAMASHITATS, MYERSCM, BLUMERJL. Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis. Antimicrob Agents Chemother1985; 27: 583–8.
BLOOMERHA, BARTONLJ, MADDOCKK.Penicillin-induced encephalopathy in uremic patients. JAMA1967; 200: 121–3.
27.
ERONLJ, HIXONDL, PARKCH, GOLDENBERGRI, PORETZDM. Imipenem versus moxalactam in the treatment of serious infection. Antimicrob Agents Chemother1983; 24: 841–6.
28.
Scandinavian Study Group.Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Lancet1984; 1: 868–71.
29.
MARIERRL, MCCLOSKEYRV, DICKERSONG, etal. Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin. J Antimicrob Chemother1983; 12: 133–9.
30.
BAUMGARTNERJD, GLAUSERMP. Comparative study of imipenem in severe infections. J Antimicrob Chemother1983; 12: 141–8.
31.
SOLOMKINJS, FANTWK, RIVERAJO, ALEXANDERJW. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 76(6A): 85–91.
32.
FASSRJ, FREIMEREH, MCCLOSKEYRV. Treatment of skin and soft tissue infections with imipenem/cilastatin. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 110–2.
33.
MARIERRL. The role of imipenem/cilastatin in the treatment of soft tissue infections. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 140–4.
34.
DICKINSONG, RODRIQUEZK, ARCEYS, ALAEA, GREENMANR.Efficacy of imipenem/cilastatin in endocarditis. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 117–21.
35.
DONABEDIANH, FREIMEREH. Pathogenesis and treatment of endocarditis. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 127–33.
36.
BERKELEYAS, FREEDMANK, HIRSCHJ, LEDGERWJ. Imipenem/cilastatin in the treatment of obstetric and gynecologic infections. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 79–84.
37.
COXCE, CORRADOML. Safety and efficacy of imipenem/cilastatin in the treatment of complicated urinary tract infections. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 92–4.
38.
TALLYFP, GORBACHSL. Therapy of mixed anaerobic-aerobic infections. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 145–53.
39.
MACGREGORRR, GENTRYLO. Imipenem/cilastatin in the treatment of osteomyelitis. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 100–3.
40.
GENTRYLO. Role of newer beta-lactam antibiotics in the treatment of osteomyelitis. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 134–9.
41.
ERONLJ. Imipenem/cilastatin therapy of bacteremia. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 95–9.
42.
SALATARA, GEBHARTRL, PALMERDL, etal. Pneumonia treated with imipenem/cilastatin. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 104–9.
43.
IANNINIPB, KUNKLEMJ, HILTONE, IANNINIGM. Imipenem/cilastatin: general experience in a community hospital. Proceedings of a symposium. Carbapenems: a new class of antibiotics. Am J Med1985; 78(6A): 122–6.
